CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 170 enrolled
Drug / intervention
Cabazitaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01505868
NCT01505868Phase 2Completed

An Open Label Phase I/II Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer

M.D. Anderson Cancer Center·interventional·Posted Jan 9, 2012·Updated Jul 30, 2021

In Brief

A Phase 2 clinical trial evaluating Cabazitaxel, Carboplatin, and 1 other intervention for Castration Levels of Testosterone and 6 related conditions. Completed, enrolled 170 participants across 2 sites.

Detailed Summary

This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment with hormones. Drugs used in chemotherapy, such as cabazitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cabazitaxel alone or with carboplatin is more effective in treating prostate cancer.

Study Details

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 9, 2012
Enrollment StartJul 11, 2012
Primary CompletionDec 9, 2019
TodayJul 2, 2026
Enrollment to primary: 7.4 yearsPosted 14.5 years ago

Interventions

Cabazitaxeldrug

Given IV

Carboplatindrug

Given IV

Laboratory Biomarker Analysisother

Correlative studies